COMMUNIQUÉS West-GlobeNewswire

Hinge Bio to Present Latest Results of HB2198, a Novel B-Cell Depleting Agent for Treating Autoimmune Disease, at ACR Convergence 2026
02/11/2026
Early clinical data and additional preclinical data of HB2198 will be presented at the American College of Rheumatology (ACR) Convergence 2026 REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Hinge Bio, Inc., a [...]
Tonix Pharmaceuticals Appoints George Lederman, Ph.D., as Executive Vice President of Strategy and Transformation
02/11/2026
Former McKinsey associate partner and Aliaxis strategy leader to lead AI initiatives and pursue partnerships to advance pipeline programs BERKELEY HEIGHTS, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals [...]
Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
02/11/2026
WELLESLEY HILLS, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that [...]
Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement
02/11/2026
BOSTON and SAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small [...]
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
02/11/2026
BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that [...]
Spectral Medical Inc. Announces Closing of First Tranche of $14.0 Million Convertible Note Private Placement, Conversion of US$4.5 Million of Maturing Convertible Notes and Repayment of US$4.5 Million of Maturing Convertible Notes
02/11/2026
TORONTO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“ Spectral ” or the “ Company ”) (TSX: EDT), a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic [...]
Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results
02/11/2026
$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch VYJUVEK pricing negotiations in Germany and Italy completed KB113 clinical data demonstrate regression in more than 80% of assessed basal cell [...]
Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution
02/11/2026
Commercial launch follows successful pilot, with customers reporting improved clinical decision-making and greater confidence in care decisions SUNNYVALE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq [...]
Conavi Medical Completes First U.S. Commercial Placement and Clinical Cases with its OCTIV™ Hybrid Imaging System to Guide Coronary Interventions
02/11/2026
Dr. Megha Prasad and fellow physicians at NewYork-Presbyterian and Columbia complete first clinical cases with Conavi’s next-generation FDA-cleared hybrid IVUS–OCT imaging system Company introduces OCTIV™, powered by [...]
Kamada to Announce Third Quarter and Nine Months Ended September 30, 2026, Financial Results on November 9, 2026
02/11/2026
Company to Host Conference Call at 8:30am ET REHOVOT, Israel and HOBOKEN, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of [...]
Vireo Growth to Report Third Quarter 2026 Financial Results on November 10, 2026
02/11/2026
MINNEAPOLIS, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), today announced that the Company will host a conference call on Tuesday, November 10, 2026, at 8:00 [...]
Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
02/11/2026
Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-year growth AUVELITY ® 3Q 2026 net product sales of $207.6 million, representing 53% year-over-year growth SUNOSI ® 3Q 2026 net product [...]
Alvotech to Present at Upcoming Investor Conferences in November
02/11/2026
REYKJAVIK, Iceland, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, [...]
Alvotech to Present at Upcoming Investor Conferences in November
02/11/2026
REYKJAVIK, ICELAND (November 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced [...]
Kraig Biocraft Laboratories Takes Spider Silk Optimization Beyond Genetics with New Dietary Additive Program
02/11/2026
Program Adds Targeted Nutrition to Genetic Engineering to Fuel Spider Silk Proteins ANN ARBOR, Mich., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or " [...]
uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease
02/11/2026
~ FDA sets PDUFA target action date of May 1, 2027 ~ ~ If approved, ifezuntirgene inilparvovec will be the world’s first disease-modifying treatment for Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, Nov. 02, [...]
Bavarian Nordic Awarded Multi-Year Vaccine Contract by UK Government
02/11/2026
COPENHAGEN, Denmark, November 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has been awarded a new multi-year contract by the UK Government through the UK Health Security Agency (UKHSA) for the [...]
GENFIT présentera ses avancées dans l’ACLF et dans le diagnostic de la MASH lors du congrès AASLD The Liver Meeting® 2026
02/11/2026
ACLF : une stratégie thérapeutique multicibles en développement GENFIT organisera un événement scientifique le 8 novembre 2026 pour présenter sa stratégie dans l’ACLF et le dossier clinique l’ayant conduit à engager [...]
GENFIT to Highlight Progress in ACLF and MASH Diagnostics at AASLD The Liver Meeting® 2026
02/11/2026
ACLF – Advancing a multi-target therapeutic strategy GENFIT to host a scientific event on November 8, 2026 to outline its ACLF strategy and unveil a comprehensive clinical data package supporting the advancement of [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum